Q3 Earnings Forecast for ELVN Issued By HC Wainwright

Key Points

• HC Wainwright expects Enliven Therapeutics to report a Q3 2026 loss of $0.41 per share and maintains a Buy rating with a $73 price target. The firm projects a $1.74-per-share loss for fiscal 2026.
• Enliven’s latest quarterly results missed expectations, with a loss of $0.49 per share versus the consensus estimate of $0.39. Analysts overall remain moderately bullish, with an average price target of $75.44.
• Institutional ownership is high at 95.08%, while insiders sold approximately $10.8 million of shares during the past quarter. The company is developing targeted cancer therapies, including ELVN-001 and ELVN-002.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Equities researchers at HC Wainwright issued their Q3 2026 earnings per share estimates for Enliven Therapeutics in a note issued to investors on Monday, October 19th. HC Wainwright analyst R. Burns expects that the company will earn ($0.41) per share for the quarter. HC Wainwright has a "Buy" rating and a $73.00 price objective on the stock. The consensus estimate for Enliven Therapeutics' current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for Enliven Therapeutics' Q4 2026 earnings at ($0.46) EPS, FY2026 earnings at ($1.74) EPS, Q1 2027 earnings at ($0.48) EPS, Q2 2027 earnings at ($0.50) EPS, Q3 2027 earnings at ($0.52) EPS and Q4 2027 earnings at ($0.55) EPS.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10).

A number of other equities analysts have also recently commented on the stock. Guggenheim reaffirmed a "buy" rating on shares of Enliven Therapeutics in a research report on Thursday, October 8th. JPMorgan Chase & Co. assumed coverage on shares of Enliven Therapeutics in a report on Thursday, October 1st. They issued an "overweight" rating and a $75.00 price objective on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Enliven Therapeutics in a research report on Thursday, October 15th. Morgan Stanley assumed coverage on shares of Enliven Therapeutics in a research report on Friday, October 2nd. They issued an "overweight" rating and a $70.00 price objective on the stock. Finally, JonesTrading raised their target price on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the stock a "buy" rating in a research note on Monday, June 29th. Ten analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Enliven Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $75.44.

Enliven Therapeutics Price Performance

ELVN stock opened at $41.25 on Wednesday. Enliven Therapeutics has a 1-year low of $14.78 and a 1-year high of $62.32. The business's 50 day simple moving average is $51.25 and its 200 day simple moving average is $47.98.

Insider Activity

In other news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $50.35, for a total transaction of $303,006.30. Following the transaction, the chief financial officer owned 38,000 shares in the company, valued at approximately $1,913,300. This trade represents a 13.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the sale, the director directly owned 87,373 shares of the company's stock, valued at approximately $5,260,728.33. The trade was a 64.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 183,831 shares of company stock valued at $10,823,298. 3.00% of the stock is owned by insiders.

Institutional Trading of Enliven Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Enliven Therapeutics during the second quarter worth $221,255,000. First Light Asset Management LLC lifted its position in shares of Enliven Therapeutics by 574.1% during the 2nd quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company's stock valued at $69,058,000 after acquiring an additional 1,158,883 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Enliven Therapeutics by 276.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company's stock worth $52,898,000 after acquiring an additional 847,399 shares in the last quarter. Siren L.L.C. bought a new stake in Enliven Therapeutics during the 1st quarter valued at $29,252,000. Finally, Jupiter Topco LLC acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter worth about $30,617,000. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven's pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.